Showing results (31-40 of 172) with videos related to
Sort By:
Pageof 18
Leukemia & Lymphoma|February 23, 2016
A single-center retrospective analysis of first-line therapy of multiple myeloma with bendamustine-bortezomib-dexamethasoneHannes Zwickl, Elisabeth Zwickl-Traxler, Martin PecherstorferBest Practice & Research. Clinical Haematology|July 20, 2005
Cytokines and signal transductionTeru Hideshima, Klaus Podar, Dharminder Chauhan, et al.Expert Opinion on Pharmacotherapy|February 14, 2012
Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignanciesSonia Vallet, Mathias Witzens-Harig, Dirk Jaeger, et al.Expert Opinion on Therapeutic Targets|June 7, 2005
Targeting signalling pathways for the treatment of multiple myelomaKlaus Podar, Teru Hideshima, Dharminder Chauhan, et al.Cancers|October 13, 2021
Management of Adverse Events and Supportive Therapy in Relapsed/Refractory Multiple MyelomaSamantha Pozzi, Alessia Bari, Martin Pecherstorfer, et al.Oncology Letters|June 12, 2025
Real-world evidence of imatinib treatment in younger and older patients with chronic myeloid leukaemia: A retrospective single centre analysisRebecca Graf, Gudrun Kreye, Martin Pecherstorfer, et al.Molecular and Clinical Oncology|December 6, 2024
Treatment of stage IV colorectal cancer: A retrospective cohort study assessing whether failure of first‑line treatment indicates failure of second‑line treatmentHanna Peyerl, Gudrun Kreye, Martin Pecherstorfer, et al.Expert Review of Anticancer Therapy|April 13, 2007
Targeting the vascular endothelial growth factor pathway in the treatment of multiple myelomaKlaus Podar, Paul G Richardson, Dharminder Chauhan, et al.Expert Opinion on Therapeutic Targets|March 23, 2025
Can we develop effective direct or indirect inhibitors of transcription factors? On the clinical evolution of protein degraders for multiple myeloma therapyRajeshwari Meli, Osman Aksoy, Sonia Vallet, et al.Expert Opinion on Investigational Drugs|October 10, 2007
The therapeutic role of targeting protein kinase C in solid and hematologic malignanciesKlaus Podar, Marc S Raab, Dharminder Chauhan, et al.Pageof 18